Pelthos Therapeutics Inc. · AMEX:PTHS
Pelthos Therapeutics — Q1 2026 Earnings Presentation
28 slides from Pelthos Therapeutics's earnings presentation, May 14, 2026
Slide 1: Corporate Presentation
Corporate Presentation M A Y 2 0 2 6 1
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation of Pelthos Therapeutics Inc. (“we”, “us”, “our” or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “anticipate,” “believe,” “continue,” “could,” “estima
Slide 3: Investment Highlight
Investment Highlight Commercial biopharmaceutical company focused on growing, differentiated cutaneous infections product portfolio Highly synergistic Xepi and Xeglyze product acquisitions leverage Zelsuvmi’s current commercial and market access team and infrastructure Strong potential revenue
Slide 4: Corporate Profile
Corporate Profile Pelthos is a competitive drug portfolio company — committed to Key Data Points commercializing innovative, safe, and efficacious therapeutic products to (as of 05/11/26, except where noted) help patients with unmet dermatological treatment burdens Ticker PTHS Stock Price $26.85 Zel
Slide 5: Management Team
Management Team Scott Plesha | Chief Executive Officer • >30 years of experience in the pharmaceutical industry, including two decades building and leading specialty pharma commercial efforts • President and Chief Commercial Officer at BDSI until it was acquired by Collegium Pharmaceutical in 2022 •
Slide 6: Molluscum & Zelsuvmi Overview
Molluscum & Zelsuvmi Overview
Slide 7: Molluscum Contagiosum
Molluscum Contagiosum A highly infectious viral condition primarily affecting children 1 year of age or older Point prevalence of Molluscum Contagiosum 3-6 million children MC can take up to (ages 0-16) in the is caused by a pox virus and is five years to resolve characterized by small, round, U.S.
Slide 8: Zelsuvmi Has the Potential to Shift MC Treatment Paradigm
Zelsuvmi Has the Potential to Shift MC Treatment Paradigm The 1st & Only At Home Prescription Treatment Previous Treatment Options • Other available topical treatment • Daily application that can be started requires in-office visits every 3 weeks2 immediately • Attractive safety profile demonstrated
Slide 9: Zelsuvmi Efficacy Shown in Phase 3 Clinical Trials Drives Commercial Launch
Zelsuvmi Efficacy Shown in Phase 3 Clinical Trials Drives Commercial Launch Population Intervention Key Study Highlights 808 Males, 790 Females Patients who applied Zelsuvmi for 12 weeks 1,598 participants randomized achieved a mean and median reduction in lesion count of 58% and 82%, respectively,
Slide 10: Phase 3 Trial Results
Phase 3 Trial Results Zelsuvmi showed statistically significant benefit vs. vehicle after 2 weeks of therapy and through out the entire 12-week length of the Phase 3 studies Least Squares Mean Lesion Reduction(1) Median Lesion Reduction (2) Baseline Week 2 Week 4 Week 8 Week 12 Baseline Week 2 Week
Slide 11: Zelsuvmi Commercial Overview
Zelsuvmi Commercial Overview
Slide 12: Strong Zelsuvmi Quarter over Quarter Growth Continues
Strong Zelsuvmi Quarter over Quarter Growth Continues Zelsuvmi TRx Units Zelsuvmi Prescriber Count 9,000 3,500 7,884 3,228 8,000 3,000 7,000 6,312 2,500 2,377 6,000 5,000 2,000 4,000 1,223 1,500 2,578 3,000 1,000 2,000 500 1,000 0 0 2025-Q3 2025-Q4 2026-Q1 2025-Q3 2025-Q4 2026-Q1 Total of 16,774 Pre
Slide 13: Zelsuvmi Covered Lives by Quarter
Zelsuvmi Covered Lives by Quarter* 100.00% 90.00% 99% 80.00% 70.00% 60.00% 50.00% 59% 40.00% 30.00% 20.00% 10.00% 0.00% Commercial Medicaid Q3 2025 Q4 2025 Q1 2026 • Selective contracting strategy • 70% combined Medicaid/commercial coverage with 1 • Commercial, Cash and Assistance Programs - 71% of
Slide 14: Strong Sales Team Execution
Strong Sales Team Execution Fully built out commercial team: • 64 Sales Territories expansion completed & onboarded covering ~53% of MC Claims • Territories expansion complete, contributing to • Zelsuvmi growth • Sales Team targeting: Pediatric/Adult Dermatologists, General Pediatrics, Nurse Practit
Slide 15: Robust Zelsuvmi Tactical Execution
Robust Zelsuvmi Tactical Execution National & Regional Conference YouTube Promotional Commercial New Patient Testimonials & Presence Information Live & Virtual ZELSUVMI GO Digital Marketing Educational Speaker Development Patient Support Program 15
Slide 16: Xepi: New Product Acquisition
Xepi: New Product Acquisition
Slide 17: Xepi (ozenoxacin) Cream for the treatment of Impetigo
Xepi (ozenoxacin) Cream for the treatment of Impetigo Acquired from BioFrontera FDA Approved in 2017 Exclusivity until 2032 in October 2025 Xepi Clinical Story Impetigo Facts1 Pelthos Opportunity • Ozenoxacin cream 1% developed • #1 bacterial infection seen in • Strong synergy with existing as first
Slide 18: Xeglyze: New Product Acquisition
Xeglyze: New Product Acquisition
Slide 19: Xeglyze (abametapir) Lotion for the Treatment of Head Lice
Xeglyze (abametapir) Lotion for the Treatment of Head Lice Acquired from Hatchtech in FDA Approved in 2020 Exclusivity until 2034 December 2025 Xeglyze Clinical Story Head Lice Facts1 Pelthos Opportunity • Abametapir lotion 0.74% • 100m+ infestations globally, with • Strong synergy with existing dev
Slide 20: Summary Financial Statements
Summary Financial Statements
Slide 21: Summary Balance Sheet
Summary Balance Sheet Notes • Cash balance includes $30 million raised with Horizon Loan Facility in January 2026 with issuance of 5-year term notes; additional tranches totaling $20 million available on hitting certain milestones • Working capital of $44.8 million as of March 31, 2026 • Strong stoc
Slide 22: Summary Income Statement
Summary Income Statement Notes • Net product revenue increased 17% quarter over quarter • SG&A expenses increased 14% quarter over quarter, related primarily to personnel costs, marketing, and manufacturing expenses • SG&A includes royalties and non-cash expenses (stock- based compensation and depre
Slide 23: Appendix
Appendix Y a Pelthos
Slide 24: Nitricil Platform Pipeline
Nitricil Platform Pipeline* Indication Asset Description Approximate Time to NDA Filing Berdazimer topical cream, dose TBD, for treatment of mild to SB414 moderate atopic dermatitis. 7.5 years (AD/Psoriasis) Phase 1/2 Clinical stage. SB208 Low alcohol berdazimer topical gel for treatment of athlete’
Slide 25: NaV1.7 Pipeline
NaV1.7 Pipeline Approximate Time to NDA Indication Asset Description Filing CT2000 Eye Drops CC8464 1%, 1.25% and 1.5% ophthalmic solution 3-4 years Chronic Ocular Pain Phase 1-2a ready CT2000 Eye Drops CC8464 1%, 1.25% and 1.5% ophthalmic solution 2-3 years Acute Ocular Pain Phase 1-2a ready CT3000
Slide 26: Board of Directors
Board of Directors Peter Greenleaf, Chairman Richard Baxter Todd Davis Andrew Einhorn Ezra Friedberg Richard Malamut , MD Matt Pauls Scott Plesha 26
Slide 27: Key Highlights
Key Highlights Portfolio of FDA Approved Differentiated portfolio of novel, cutaneous infectious disease products, including Zelsuvmi, Products Xepi and Xeglyze for the treatment of MC, impetigo and head lice, respectively Significant Unmet Need and Each Pelthos product is differentiated from existi
Slide 28: Thank You
Thank You Contacts Investor Inquiries: Mike Moyer LifeSci Advisors, LLC Managing Director mmoyer@lifesciadvisors.com Media: KWM Communications Kellie Walsh / Rachel Kessler pelthos@kwmcommunications.com (914) 315-6072 28